Notes
Built from three sources per the contract. (1) ADCdb DRG0EGQMP: target FOLR1 (TAR0QHAVI), payload exatecan (PAY0LEIGJ, TOP1 inhibitor), DAR "7 to 8", sponsor Bio-Thera, Phase 1/2, NCT05378737; ADCdb does NOT disclose antibody name, isotype, linker name/class/attachment, conjugation, or a linker LIN cross-ref (all left blank). (2) Clinical: ASCO 2024 abstract #5550 (J Clin Oncol 42:16_suppl 5550) + Bio-Thera/PRNewswire press release, and the ASCO 2025 #5517 poster (PROC dose-optimization update, BAT-8006-001-CR, data cut 2025-04-30) which provides the cleanest >=Grade 3 TEAE table by dose cohort. Dosing is IV Q3W at two optimization doses 84 and 93 mg/m2 (BSA-based); 84 mg/m2 (n=87) selected as the better-tolerated, RP3D-aligned cohort and tagged RP2D/line_context=RP2D. The 93 mg/m2 comparator rates are noted per-row. (3) PubChem CID 151115 (exatecan): MW 435.4, XLogP3 0.4, TPSA 106, C24H22FN3O4; bystander = Yes (membrane-permeable). OCULAR: triage explicit-zero confirmed and reinforced by a second independent readout — ASCO 2024 'no ILD/pneumonitis and keratitis, uveitis, decreased vision was reported' and ASCO 2025 conclusion 'no ILD/ocular toxicity was reported.' oae_any_pct set to 0 with documented note; ocular_surface_subtype=None. This is a valuable negative/control case because FRalpha is the mirvetuximab soravtansine (DM4) target which carries high corneal keratopathy, whereas the exatecan (TOP1) payload here shows no ocular signal. CAVEATS: any-grade TRAE rates (anemia 82%, leukopenia 80%, neutropenia 77%, vomiting 67%, nausea 60%, thrombocytopenia 55%) come from the ASCO 2024 abstract summary (tier C); the granular >=G3 by-dose figures are tier B from the 2025 poster. Linker is described only as 'proprietary systemically-stable cleavable linker' — class=Cleavable but no enzyme specificity, attachment chemistry, or LIN id is public, so adcdb linker fields and conjugation_method are blank. Not filling derived columns per instructions.